RT Journal Article
SR Electronic
T1 Comparative evaluation of rapid isothermal amplification and antigen assays for screening testing of SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.16.21267796
DO 10.1101/2021.12.16.21267796
A1 Salcedo, Nol
A1 Sena, Brena F.
A1 Qu, Xiying
A1 Herrera, Bobby Brooke
YR 2021
UL http://medrxiv.org/content/early/2021/12/17/2021.12.16.21267796.abstract
AB Human transmission of SARS-CoV-2 and emergent variants of concern has continued to occur globally, despite mass vaccination campaigns. Public health strategies to reduce virus spread should therefore rely, in part, on frequent screening with rapid, inexpensive, and sensitive tests. We evaluated two digitally integrated rapid tests and assessed their performance using stored nasal swab specimens collected from individuals with or without COVID-19. An isothermal amplification assay combined with a lateral flow test had a limit of detection of 10 RNA copies per reaction, and a positive percent agreement (PPA)/negative percent agreement (NPA) during the asymptomatic and symptomatic phases of 100%/100% and 95.83/100%, respectively. Comparatively, an antigen-based lateral flow test, had a limit of detection of 30,000 copies, and a PPA/NPA during the asymptomatic and symptomatic phases of 82.86%/98.68% and 91.67/100%, respectively. Both the isothermal amplification and antigen-based lateral flow tests had optimized detection of SARS-CoV-2 during the peak period of transmission; however, the antigen-based test had reduced sensitivity in clinical samples with qPCR Ct values greater than 29.8. Low-cost, high-throughput screening enabled by isothermal amplification or antigen-based techniques have value for outbreak control.Competing Interest StatementNS, BFS, and BBH are employed by E25Bio, Inc., a company that develops rapid diagnostic tests for infectious diseases. At the time of the study, XQ was employed by E25Bio, Inc. BBH is an inventor on a U.S. Provisional Patent Application (63/189,502).Funding StatementThis work was supported by E25Bio, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The primary studies under which the dilution specimens samples were collected received ethical clearance from the PATH Institutional Review Board (IRB) (approval number 0004244). Additionally, collection of nasal swab specimens received ethical clearance from the Advarra, Inc. IRB (approval number Pro00044496). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data have been included in the manuscript. We will provide any additional data upon request.